Study the effect of vana tulsi in seizure disorder.

To study the clinical effect of Ocimum Besilicum L (Vana Tulsi) in the management of Seizure disorder.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/035018

Enrollment

Registered

2021-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G40- Epilepsy and recurrent seizures

Interventions

Intervention1: Vana Tulsi (Ocimum besilicum) Tail: Patients will receive intranasally 2 drops each nostril once daily for 3 months followed by follow up of 6 months(total duration of study 9 months) C

Eligibility

Inclusion criteria

Inclusion criteria: (1)Patient with clinical manifestation of disease. (2)Age group 5 to 16 years (3)Patient who were previously diagnosed and have reliable reports.

Exclusion criteria

Exclusion criteria: (1) Onset of seizure. (2) Patient below 5 years and above 16 years. (3) progressive neurological disease. (4) Systemic illness like heart, renal, hepatic diseases.

Design outcomes

Primary

Measure	Time frame
Comparing the severity and frequency of seizure before and after intervention.Timepoint: At the end of 9 months	—

Secondary

Measure	Time frame
Change in subjective and objective parameters after treatment.Timepoint: At the end of 9 months.	—

Countries

India

Contacts

Public ContactDr Prashant kumar Gupta

Shri Narayan Prasad Awasthi government ayurved college Raipur Chhattisgarh.

singhgyanendrabaghel@gmail.com9425215815

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026